Precigen Is Owed $96.5 Million On 127-Day Payment Terms, Nearly All Of It By One Wholesaler

Receivables jumped from $3.9 million at year-end, and nine-month operating cash flow is still negative $49.8 million despite profit.

Share
Precigen Is Owed $96.5 Million On 127-Day Payment Terms, Nearly All Of It By One Wholesaler

Trade receivables at Precigen, maker of the rare-disease therapy Papzimeos, reached $96.5 million at September 30, against $3.9 million at December 31, 2025, the company's 10-Q filed Wednesday shows. About 99% of the receivables sit with a single wholesaler, and the company gives customers 127 days to pay.

Profit on paper, cash outflow in practice

Precigen reported net income of $47.9 million for the first nine months, yet operating activities consumed $49.8 million of cash, against $64.4 million used a year earlier. The company says changes in operating assets and liabilities used $112.2 million, driven mainly by growth in receivables and inventory as Papzimeos sales ramped, and ties the receivables build to the 127-day terms.

At six months, operating cash flow stood at negative $61.6 million, according to the prior filing. Management reports positive operating cash flow of $11.9 million for the third quarter alone.

Third-quarter revenue was $74.1 million, including $72.9 million of net Papzimeos product revenue, against $2.9 million total a year earlier. Operating income was $38.7 million for the quarter.

One wholesaler holds 99% of the receivables

The company sells all Papzimeos product through a large commercial pharmaceutical wholesaler that it says holds an investment-grade credit rating. That wholesaler accounted for about 99% of receivables at September 30, up from about 89% at year-end.

Precigen, which develops gene and cell therapies, won full FDA approval for Papzimeos in August 2025 for adults with recurrent respiratory papillomatosis, a rare disease caused by chronic HPV 6 or HPV 11 infection. It estimates about 27,000 adult patients in the United States live with the disease.

Cash cushion and a rival drug

Cash, cash equivalents and investments totaled $51.0 million at September 30, up from $38.7 million at June 30, while long-term debt carried at $94.3 million has $100 million of principal outstanding. Management says cash plus anticipated receivable collections will fund operations for at least one year.

With its cheaper pre-launch stock now essentially gone, Precigen expects Papzimeos cost of products to climb relative to revenue. In September, the FDA granted platform technology designation to its AdenoVerse platform.

Yahoo Finance reported that the FDA's approval of Inovio's rival drug for the disease sent Precigen shares down 27% after hours. The company's market value stood at $1.9 billion.

Precigen's own filing says its path to sustained profitability depends on continued successful commercialization of Papzimeos, and its stated plan to finance cash needs starts with collecting those receivables.

Sources